NBY - NovaBay Pharmaceuticals Stock Price, News & Analysis

$4.35 -0.10 (-2.25 %)
(As of 11/24/2017 01:31 PM ET)
Previous Close$4.45
Today's Range$4.35 - $4.54
52-Week Range$2.25 - $5.00
Volume3,900 shs
Average Volume16,771 shs
Market Capitalization$72.27 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.69

About NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)

NovaBay Pharmaceuticals logoNovaBay Pharmaceuticals, Inc., formerly NovaCal Pharmaceuticals, Inc., is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox. Its Avenova with Neutrox removes debris from the skin on the eyelids and lashes without burning or stinging. It develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. Its Aganocide compounds, led by auriclosene (NVC-422), are synthetic molecules with activity against bacteria, viruses and fungi. The Company's dermatology product includes CelleRx, a cleansing solution for post laser resurfacing, chemical peels and other cosmetic surgery procedures. Its wound care business includes the business of NeutroPhase product.


Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNYSEAMERICAN:NBY
CUSIPN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS($0.83)
Net IncomeN/A
Net Margins-42.16%
Return on Equity-184.30%
Return on Assets-56.33%

Miscellaneous

EmployeesN/A
Outstanding Shares15,370,000

Frequently Asked Questions for NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)

What is NovaBay Pharmaceuticals' stock symbol?

NovaBay Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NBY."

When did NovaBay Pharmaceuticals' stock split? How did NovaBay Pharmaceuticals' stock split work?

NovaBay Pharmaceuticals shares reverse split on the morning of Monday, December 21st 2015. The 1-25 reverse split was announced on Friday, December 11th 2015. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 18th 2015. An investor that had 100 shares of NovaBay Pharmaceuticals stock prior to the reverse split would have 4 shares after the split.

How were NovaBay Pharmaceuticals' earnings last quarter?

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) announced its quarterly earnings results on Tuesday, November, 14th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.07) by $0.09. The biopharmaceutical company had revenue of $4.09 million for the quarter, compared to analyst estimates of $4.69 million. NovaBay Pharmaceuticals had a negative return on equity of 184.30% and a negative net margin of 42.16%. View NovaBay Pharmaceuticals' Earnings History.

Where is NovaBay Pharmaceuticals' stock going? Where will NovaBay Pharmaceuticals' stock price be in 2017?

5 Wall Street analysts have issued 1-year price targets for NovaBay Pharmaceuticals' stock. Their forecasts range from $5.00 to $8.00. On average, they anticipate NovaBay Pharmaceuticals' stock price to reach $6.25 in the next twelve months. View Analyst Ratings for NovaBay Pharmaceuticals.

What are Wall Street analysts saying about NovaBay Pharmaceuticals stock?

Here are some recent quotes from research analysts about NovaBay Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of antimicrobial compounds, which it has named Aganocide compounds, which are based upon small molecules that are generated by white blood cells that defend the body against invading pathogens. NovaBay believes that Aganocide compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of bacterial and viral infections, including Methicillin-Resistant Staphylococcus aureus. " (10/12/2017)
  • 2. Maxim Group analysts commented, "NovaBay reported 4Q16 revenue of 4M, inline with preannouncement back in January. Operating expenses were $6.1M up from the prior quarter's $5.5M. This translated into a net loss of $1.6M or $(0.11) per share. Novabay ended the quarter with $9.5M in cash or about $7M (est.) in cash today... We have adjusted our model to reflect the revenue guidance. We conclude that without a revenue breakout, (driven by additional capital), our model suggests a target valuation in the current range. As such, we maintain our Hold rating." (3/24/2017)

Who are some of NovaBay Pharmaceuticals' key competitors?

Who are NovaBay Pharmaceuticals' key executives?

NovaBay Pharmaceuticals' management team includes the folowing people:

  • Mark M. Sieczkarek, Interim Chairman of the Board, President, Chief Executive Officer
  • John McGovern, Chief Financial Officer, Treasurer
  • Justin M. Hall Esq., Senior Vice President, General Counsel
  • Xinzhou Li, Director
  • Xiaoyan Liu, Director
  • Yonghao Ma Ph.D., Director
  • , Bio & Compensation - 
  • Mijia Wu, Director
  • Todd E. Zavodnick, Director

How do I buy NovaBay Pharmaceuticals stock?

Shares of NovaBay Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NovaBay Pharmaceuticals' stock price today?

One share of NovaBay Pharmaceuticals stock can currently be purchased for approximately $4.35.

How big of a company is NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals has a market capitalization of $72.27 million.

How can I contact NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals' mailing address is 2000 Powell St Ste 1150, EMERYVILLE, CA 94608-1804, United States. The biopharmaceutical company can be reached via phone at +1-510-8998800.


MarketBeat Community Rating for NovaBay Pharmaceuticals (NBY)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  71 (Vote Outperform)
Underperform Votes:  65 (Vote Underperform)
Total Votes:  136
MarketBeat's community ratings are surveys of what our community members think about NovaBay Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 4 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $6.25

Consensus Price Target History for NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)

Price Target History for NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)

Analysts' Ratings History for NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)

Show:
DateFirmActionRatingPrice TargetDetails
11/15/2017LaidlawLower Price TargetBuy -> Buy$10.00 -> $8.00View Rating Details
11/15/2017HC WainwrightSet Price TargetBuy$6.00View Rating Details
10/23/2017Roth CapitalSet Price TargetBuy$5.00View Rating Details
8/11/2017Maxim GroupReiterated RatingHoldView Rating Details
2/6/2017Rodman & RenshawInitiated CoverageBuy$6.00View Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)

Earnings by Quarter for NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)

Earnings History by Quarter for NovaBay Pharmaceuticals (NYSEAMERICAN NBY)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2017Q3($0.07)($0.16)$4.69 million$4.09 millionViewN/AView Earnings Details
8/10/2017Q2 2017($0.12)($0.11)$4.57 million$4.12 millionViewN/AView Earnings Details
11/10/2016Q316($0.16)($0.34)$3.02 million$3.40 millionViewN/AView Earnings Details
8/11/2016Q216($0.30)($0.36)$1.76 million$2.70 millionViewListenView Earnings Details
5/12/2016Q116($0.68)($1.24)$1.84 million$1.70 millionViewListenView Earnings Details
3/3/2016Q415($1.36)($1.26)$1.43 million$1.60 millionViewN/AView Earnings Details
11/19/2015Q315($0.07)($0.07)$1.06 million$1.20 millionViewListenView Earnings Details
8/13/2015Q215($0.07)($0.07)$610.00 millionViewListenView Earnings Details
5/14/2015Q1($0.06)($0.09)ViewN/AView Earnings Details
3/26/2015Q414($0.07)($0.09)ViewN/AView Earnings Details
11/12/2014Q314($0.09)($0.08)ViewN/AView Earnings Details
7/31/2014($0.09)($0.06)ViewN/AView Earnings Details
5/1/2014Q114($0.11)($0.08)ViewN/AView Earnings Details
11/12/2013Q3($0.10)ViewN/AView Earnings Details
5/2/2013Q113($0.07)($0.11)$1.18 millionViewN/AView Earnings Details
3/14/2013Q4 2012($0.09)($0.08)$1.50 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for NovaBay Pharmaceuticals (NYSEAMERICAN NBY)

Insider Trades by Quarter for NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)

Insider Trades by Quarter for NovaBay Pharmaceuticals (NYSEAMERICAN NBY)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/25/2017Jacques BonneauDirectorBuy25,000$0.22$5,500.00
10/18/2017Jacques BonneauDirectorBuy50,000$0.16$8,000.00
9/8/2017Jean-Sébastien DavidDirectorBuy12,300$0.20$2,460.00
9/7/2017Jean-Sébastien DavidDirectorBuy15,000$0.20$3,000.00
9/6/2017Claude DufresneDirectorBuy10,000$0.21$2,100.00
8/21/2017Claude DufresneDirectorBuy10,000$0.13$1,300.00
6/26/2017Serge SavardDirectorBuy52,000$0.18$9,360.00
6/23/2017Serge SavardDirectorBuy10,000$0.17$1,700.00
6/21/2017Serge SavardDirectorBuy18,500$0.17$3,145.00
6/20/2017Serge SavardDirectorBuy101,000$0.17$17,170.00
6/19/2017Serge SavardDirectorBuy18,500$0.17$3,145.00
4/26/2017Claude DufresneDirectorBuy2,000$0.76$1,520.00
3/6/2017Jean-Sébastien DavidDirectorBuy3,820$0.81$3,094.20
1/12/2017Claude DufresneDirectorSell21,000$0.77$16,170.00
8/20/2015Ramin NajafiCEOBuy12,000$0.47$5,640.00View SEC Filing  
3/3/2015Pharma (Singapore) Pte PioneerMajor ShareholderBuy2,590,000$0.60$1,554,000.00View SEC Filing  
3/3/2015Ramin NajafiChairmanBuy166,666$0.60$99,999.60View SEC Filing  
12/12/2014Ramin NajafiChairmanBuy50,000$0.65$32,500.00View SEC Filing  
12/12/2014Thomas J PaulsonCFOBuy10,000$0.68$6,800.00View SEC Filing  
12/11/2014Ramin NajafiChairmanBuy20,000$0.60$12,000.00View SEC Filing  
12/9/2014Thomas J PaulsonCFOBuy10,000$0.67$6,700.00View SEC Filing  
12/5/2014Ramin NajafiChairmanBuy25,000$0.65$16,250.00View SEC Filing  
12/2/2014Ramin NajafiChairmanBuy18,000$0.71$12,780.00View SEC Filing  
12/2/2014Tony D.S. WicksDirectorSell20,000$0.70$14,000.00View SEC Filing  
6/4/2014Mark M SieczkarekDirectorBuy4,800$0.89$4,272.00View SEC Filing  
5/19/2014Mark M SieczkarekDirectorBuy25,000$0.88$22,000.00View SEC Filing  
5/13/2014Pioneer Pharma Holdings ChinaMajor ShareholderBuy65,065$0.99$64,414.35View SEC Filing  
5/12/2014Pioneer Pharma Holdings ChinaMajor ShareholderBuy116,107$0.99$114,945.93View SEC Filing  
5/9/2014Pioneer Pharma Holdings ChinaMajor ShareholderBuy318,828$0.99$315,639.72View SEC Filing  
12/2/2013Pioneer Pharma Holdings ChinaMajor ShareholderBuy5,000,000$1.14$5,700,000.00View SEC Filing  
12/11/2012Xinzhou LiInsiderBuy120,000$1.20$144,000.00View SEC Filing  
12/6/2012Ramin NajafiChairmanBuy20,000$1.24$24,800.00View SEC Filing  
12/6/2012Thomas J PaulsonCFOBuy10,000$1.24$12,400.00View SEC Filing  
10/31/2012Area Pioneer Pharma Co. NaquMajor ShareholderBuy1,200,000$1.25$1,500,000.00View SEC Filing  
9/13/2012Xinzhou LiMajor ShareholderBuy800,000$1.25$1,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for NovaBay Pharmaceuticals (NYSEAMERICAN NBY)

Source:

Social Media

Social activity is not available for this stock.

Financials

Chart

NovaBay Pharmaceuticals (NYSEAMERICAN NBY) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.